Drugs for prevention and treatment of postmenopausal osteoporosis.
D015502:Absorptiometry, Photon; D000368:Aged; D019386:Alendronate / Q000009:adverse effects / Q000627:therapeutic use; D015519:Bone Density / Q000187:drug effects; D001862:Bone Resorption; D001943:Breast Neoplasms / Q000139:chemically induced / Q000453:epidemiology; D002116:Calcitonin / Q000009:adverse effects / Q000494:pharmacology; D002118:Calcium / Q000494:pharmacology; D002121:Calcium Channel Blockers / Q000009:adverse effects / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D003720:Densitometry; D004305:Dose-Response Relationship, Drug; D004967:Estrogens / Q000009:adverse effects / Q000494:pharmacology; D012968:Etidronic Acid / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D005260:Female; D006801:Humans; D008875:Middle Aged; D015663:Osteoporosis, Postmenopausal / Q000188:drug therapy* / Q000517:prevention & control*; D020849:Raloxifene Hydrochloride / Q000009:adverse effects / Q000627:therapeutic use; D000068296:Risedronic Acid; D012307:Risk Factors; D014807:Vitamin D / Q000494:pharmacology
D002121:Calcium Channel Blockers; D004967:Estrogens; D014807:Vitamin D; D020849:Raloxifene Hydrochloride; D002116:Calcitonin; D000068296:Risedronic Acid; D012968:Etidronic Acid; D002118:Calcium; D019386:Alendronate